Erenumab Improves Functional Outcomes of Episodic Migraine: LIBERTY Trial

• By the end of 12 weeks, the researchers found that erenumab significantly improved MPFID-Physical Impairment (PI) and Everyday Activities (EA) scores than placebo (treatment difference (TD) MPFID-PI: −3.5); MPFID-EA: −3.9).
• They observed that patients on erenumab were more likely to have a ≥5-point reduction in MPFID score (odds ratio [OR] vs placebo; MPFID-EA: 2.1; MPFID-PI: 2.5).
• They found that about 46.2% of patients in the erenumab group had a ≥5-point reduction in HIT-6 total score from baseline, which was nearly 2 times higher compared with 26.6% of patients in the placebo group (OR, 2.4).
• In three out of four WPAI domains, they reported that erenumab showed improvement versus placebo.

The authors concluded, "These findings, obtained via the use of patient-reported outcomes (PROs)—the MPFID-EA and PI, HIT-6, and WPAI questionnaires—corroborate the efficacy observed with erenumab in LIBERTY on traditional measures of treatment efficacy (such as the number of migraine days)."

They further added, "The findings of these analyses add to previous erenumab efficacy and safety data obtained from the LIBERTY study. They show that erenumab exerts a positive effect on patient functioning and work productivity, as assessed by PRO measures among patients with EM in whom 2–4 preventives had not been useful."

For further information:

https://jnnp.bmj.com/content/92/5/466